----
Current ValuationThe current P/E ratio is -0.71, above the reasonable range, cheaper than 3.22% of the time in the past 5 years, and the industry ranks 103/255, the industry Median -1.12.
-0.705xP/E
$3.30Stock price
$-4.68Earnings per share
-0.705xP/E
Stock price$3.30Earnings per share$-4.68
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.28x
- Typical range
- -5.06x–-1.57x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -60.94x | 144.93% | $63.66B |
BAYZFUSBayer Aktiengesellschaft | -25.04x | -- | $50.44B |
BAYRYUSBayer | -24.97x | -- | $50.30B |
VTRSUSViatris | -52.49x | 107.68% | $21.56B |
ELANUSElanco Animal Health | -56.87x | 130.52% | $11.32B |
AXSMUSAxsome Therap | -39.22x | 20.27% | $7.52B |
VREOFUSVIREO GROWTH INC | -109.29x | -- | $7.33B |
CURLFUSCuraleaf Holdings, Inc. | -124.76x | -- | $6.49B |
MANEUSVeraDermics | -57.62x | 97.44% | $6.01B |
BLTEUSBelite Bio | -58.51x | 29.87% | $5.99B |
DFTXUSDefinium Therapeutics | -14.47x | 54.55% | $5.12B |
EWTXUSEdgewise Therapeutics | -22.30x | 187.50% | $4.40B |
RGCUSRegencell Bioscience | -307.82x | -- | $3.60B |
AMLXUSAmylyx Pharmaceuticals | -23.16x | 1.76% | $3.52B |
ELVNUSEnliven Therapeutics | -30.97x | 5.59% | $3.28B |
TARSUSTarsus Pharmaceuticals | -68.03x | 345.28% | $3.16B |
MBXUSMBX Biosciences | -25.01x | 31.12% | $2.61B |
BHCUSBausch Health | -2.36x | 569.84% | $2.59B |
SUPNUSSupernus Pharma | -21.73x | 66.18% | $2.39B |
PHVSUSPharvaris BV | -11.63x | 10.43% | $2.30B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
